



Epidermal Transglutaminase (eTG/TG3) Antibody, IgA by ELISA

LABORATORIES

Patient: [REDACTED]
DOB: [REDACTED] Age: [REDACTED] Sex: [REDACTED]
Patient Identifiers: [REDACTED]
Visit Number (FIN): [REDACTED]

Client: ARUP Example Report Only
500 Chipeta Way
Salt Lake City, UT 84108
Physician: [REDACTED]

ARUP Test Code: 2010902
Collection Date: 01/22/2024
Received in lab: 01/25/2024
Completion Date: 01/25/2024

Immunodermatology Serum Test Report Navigation Guide

The Immunodermatology TESTING REPORT from the University of Utah follows "See Note" and is arranged as outlined below on the following pages:

CLINICAL INFORMATION

This content is provided by the ordering clinician and includes the reason for testing.

Specimen Details

This includes specimen identification with collected and received dates.

DIAGNOSTIC INTERPRETATION

This is a synopsis of key findings from the testing and their diagnostic relevance.

RESULTS

This section reports the discrete finding and value of each test component, along with the reference range.

COMMENTS

Specific

These comments provide an explanation of the test results as they relate to clinical considerations, and include reference to any concurrent and/or previous testing.

General

These comments summarize fundamental information about the test(s) and the component(s) assessed to aid in interpretation of their clinical applicability.

TESTING METHODS

The section lists the procedures performed, the test source(s), and the applicable laboratory developed test disclaimer(s).

TEST RESULTS SUMMARY CHART

A chart tabulating results of tests ordered for the patient by the same client is included if previous and/or concurrent testing has been performed.

ELISA RESULTS GRAPH

A graph of ELISA results also is included if previous and/or concurrent testing has been performed; the graph may be found on a subsequent page.

For testing algorithm and additional information, refer to:
arupconsult.com/content/immunobullous-skin-diseases-screening



Patient: [REDACTED]
ARUP Accession: 24-022-102580




John J. Zone, MD - Co-Director
Kristin M. Leiferman, MD - Co-Director
Mazdak Khalighi, MD
Melanie K. Kuechle, MD

Department of Dermatology
Immunodermatology Laboratory
Immunodermatology.uofumedicine.org

417 S. Wakara Way, Suite 2151
Salt Lake City, UT 84108
Phone: 1-801-581-7139 or 1-866-266-5699
Fax: 1-801-585-5695

IMMUNODERMATOLOGY LABORATORY REPORT



Submitter

ARUP Sendouts

Epidermal Transglutaminase (eTG/TG3) Antibody, IgA by ELISA (Final result)

TESTING REPORT follows "See Note"
See Note

CLINICAL INFORMATION

Skin lesions and gastrointestinal symptoms. Presumptive diagnosis is dermatitis herpetiformis.

Specimen Details

- ; Collected: 1/22/2024; Received: 1/22/2024

DIAGNOSTIC INTERPRETATION

Increased IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level by ELISA, providing support for the diagnosis of dermatitis herpetiformis

(See Results and Comments including recommendations for correlating with other testing)

RESULTS

Enzyme-Linked Immunosorbent Assay (ELISA)

Epidermal Transglutaminase (eTG/TG3) IgA Antibodies

IgA epidermal transglutaminase antibody level: 55 U/mL (H)

Copy For:
IP16938

Printed: 1/25/2024 11:04 PM
Page: 1 of 3



Patient:
ARUP Accession: 24-022-102580

PCP: Unspecified

Reference Range:

Normal (negative) = Less than 16 U/mL
Borderline/Indeterminate = 16-22 U/mL
Increased (H) (positive) = Greater than 22 U/mL

(H) = high/positive
U = antibody level in ELISA units

COMMENTS

Specific

This ELISA result, demonstrating an increased IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level, supports the diagnosis of dermatitis herpetiformis. Most patients with dermatitis herpetiformis have associated celiac disease.

Clinical correlation is needed including with direct immunofluorescence findings on a biopsy specimen and assessment of celiac disease serologies, including serum IgA endomysial antibodies by indirect immunofluorescence and IgA tissue transglutaminase (tTG), also known as transglutaminase 2 (TG2), antibodies by ELISA. If not already performed, direct immunofluorescence testing can be accomplished on a perilesional biopsy specimen submitted through ARUP Laboratories [ARUP test number 0092572, Direct Immunofluorescence, Tissue Biopsy (Cutaneous, Mucosal, Epithelial)], and testing for serum celiac disease antibodies may be accomplished by request (ARUP test number 2008114, Celiac Disease Reflexive Cascade); contact ARUP Client Services, 1-800-242-2787, option 2, for assistance.

IgA eTG/TG3 antibody levels correlate with disease activity in individual patients with dermatitis herpetiformis; monitoring antibody profiles and levels may be helpful in assessing disease expression and activity, including therapeutic response as related to restriction of gluten ingestion.

General

Epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), is the dominant antigen to which IgA antibodies develop in dermatitis herpetiformis. IgA eTG/TG3 antibodies account for the characteristic dermal IgA reactivity (subepithelial granules or fibrils discontinuously beneath the basement membrane zone with stippling in dermal papillae) observed by direct immunofluorescence in skin biopsy specimens. An increased IgA eTG/TG3 antibody level in serum is distinctly characteristic of dermatitis herpetiformis.

Levels of IgA eTG/TG3 antibodies may correlate with disease activity in individual patients with dermatitis herpetiformis. Most patients with dermatitis herpetiformis have gluten sensitivity with celiac disease and

Copy For:
IP16938

Printed: 1/25/2024 11:04 PM
Page: 2 of 3



Patient: [REDACTED]
ARUP Accession: 24-022-102580

PCP: Unspecified

characteristic IgA antibodies to tissue transglutaminase (tTG), also known as transglutaminase 2 (TG2), by ELISA, along with positive IgA endomysial antibodies by indirect immunofluorescence which correlate with disease activity. Patients with dermatitis herpetiformis can have an antibody profile specific for eTG/TG3 with higher avidity than to tTG/TG2; however, a normal IgA eTG/TG3 antibody level does not rule out the diagnosis of dermatitis herpetiformis.

TESTING METHODS

Enzyme-Linked Immunosorbent Assay (ELISA)

IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level in serum determined by ELISA (ALPCO Immunoassays). The performance characteristics of this ELISA testing were determined by the Immunodermatology Laboratory at the University of Utah. The testing has not been cleared or approved by the FDA (US Food and Drug Administration). FDA clearance or approval currently is not required for this testing performed in a CLIA-certified laboratory (Clinical Laboratory Improvement Amendments) and intended for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. [One ELISA]

Electronically signed by [REDACTED] on 01/25/24 at 11:03 PM.

Resulting Laboratory

IMMUNODERMATOLOGY LABORATORY	801-581-7139
University of Utah	
417 S. Wakara Way, Suite 2151	
Salt Lake City, UT 84108	
Director: Kristin M. Leiferman, MD	

Copy For:
IP16938

Printed: 1/25/2024 11:04 PM
Page: 3 of 3

